Jefferies analyst Maury Raycroft raised the firm’s price target on Alnylam (ALNY) to $384 from $328 and keeps a Buy rating on the shares. The firm, which is updating its model ahead of Q2 earnings, sees the potential for a guidance raise from management based on the firm’s tracking of Amvuttra’s uptake so far in the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam announces reimbursement of OXLUMO in Canada
- Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma’s Amvuttra
- Alnylam’s NeuroFeeL Study: A New Frontier in Amyloidosis Biomarker Research
- Alnylam price target raised to $377 from $320 at Needham
- Alnylam Pharma’s Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch